Chronic Hand Eczema

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.

Covering delgocitinib for chronic hand eczema could save a 1M-member plan $88M over 3 years, driven by lower drug costs than off-label therapies.

DELTA 2 data show topical delgocitinib for chronic hand eczema delivers minimal systemic absorption even under maximal-use conditions.

New US chronic hand eczema guidance closes diagnostic gaps and spotlights emerging therapies like delgocitinib to cut itch, pain, and work disruption.

Chronic hand eczema care is marked by high costs, fragmented treatment, and a clinical overreliance on steroids.

Delgocitinib led to notable improvement by week 4, which may have helped improve longer-term treatment adherence.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

CHECK-US data show chronic hand eczema is driven by multiple triggers and linked to moderate disease severity and significant quality-of-life burden.